CherfanAArabiYAl AskarAShimemeriA. Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. Pharmacotherapy. 2007;27:755-759.
4.
AronowHDSteinhublSRBrennanDMBergerPBTopolEJ; CREDO Investigators. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2009;157:369-374. doi:10.1016/j.ahj.2008.09.011.
5.
NaranjoCABustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.